nad has been researched along with Non-alcoholic Fatty Liver Disease in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (58.62) | 24.3611 |
| 2020's | 12 (41.38) | 2.80 |
| Authors | Studies |
|---|---|
| Barrès, R; Dall, M; Gillum, MP; Hassing, AS; Ingerslev, LR; Larsen, S; Mann, M; Nielsen, TS; Niu, L; Poulsen, SS; Sulek, K; Trammell, SAJ; Treebak, JT; Ørskov, C | 1 |
| Deng, KY; Gan, L; Guan, XH; Huang, CC; Li, Q; Qian, YS; Wang, LF; Wen, K; Xiao, YF; Xie, L; Xin, HB; Zhao, JL; Zhao, QH | 1 |
| Aggarwal, S; Nagarajan, P; Ramakrishna, G; Trehanpati, N | 1 |
| Fu, Z; Ibrahim, AS; Kim, H; Liu, W; Qi, NR; Shamsa, EH; Song, Z; Sun, S; Yang, Z; Yumnamcha, T; Zhang, K; Zhang, R | 1 |
| Hikosaka, K; Iqbal, T; Karim, M; Matsumoto, M; Nakagawa, T; Nawaz, A; Yaku, K | 1 |
| Aggarwal, S; Bedi, O; Maiwall, R; Maras, JS; Pamecha, V; Ramakrishna, G; Rastogi, A; Trehanpati, N; Yadav, V | 1 |
| Dong, M; Pei, Z; Wang, S | 1 |
| Chen, S; Chen, Y; Li, Y; Liu, X; Long, L; Shen, L; Tang, S; Wu, C; Yi, T; Zeng, Q; Zhong, L; Zhou, Y | 1 |
| Bock, KW | 2 |
| Guo, H; Hao, K; Jiang, W; Liu, J; Lu, L; Wang, G; Xu, S | 1 |
| He, M; Hua, R; Shao, YK; Shen, QW; Wang, GZ; Wang, M; Wu, M; Yang, YP; Yao, QY; Zang, Y; Zhang, ZY | 1 |
| Dall, M; Hassing, AS; Treebak, JT | 1 |
| Deng, KY; Guan, XH; Hu, L; Huang, CC; Qian, YS; Wang, LF; Wang, XN; Xiao, YF; Xin, HB | 1 |
| Avola, R; Barbagallo, I; Cinà, D; Currenti, W; D'Orazio, N; Galvano, F; Godos, J; Lembo, V; Li Volti, G; Morisco, F; Salomone, F | 1 |
| Auwerx, J; Cialabrini, L; De Franco, F; de Seigneux, S; Gariani, K; Giacchè, N; Ivanisevic, J; Katsyuba, E; Legouis, D; Liscio, P; Matilainen, O; Mottis, A; Pellicciari, R; Raffaelli, N; Ryu, D; Schoonjans, K; Stokar-Regenscheit, N; van der Velpen, V; Zietak, M | 1 |
| Bae, M; Hu, S; Kang, H; Kim, MB; Lee, JY; Lee, Y; Park, YK; Pham, TX | 1 |
| Harimoto, N; Ikegami, T; Konishi, H; Maehara, Y; Nakagawara, H; Oda, Y; Shirabe, K; Soejima, Y; Yamashita, Y; Yoshizumi, T | 1 |
| Akie, TE; Cooper, MP; Lei, S; Liu, L; Nam, M | 1 |
| Dall, M; Garten, A; Gorski, T; Jensen, BA; Kiess, W; Larsen, PS; Meusel, A; Penke, M; Richter, S; Schuster, S; Treebak, JT; Vienberg, SG | 1 |
| Fan, MB; Guan, YF; Hua, X; Li, GQ; Li, ZY; Liu, J; Miao, CY; Song, J; Wang, P; Xu, TY; Yang, X; Zhou, CC | 1 |
| Chao, PM; Chen, GC; Chyuan, JH; Lin, YS; Su, HM; Tsou, PY | 1 |
| Jia, L; Li, J; Li, W; Li, Y; Lu, X; Luan, Y; Ma, L; Qi, H; Song, H; Yang, Y | 1 |
| Auwerx, J; Bai, P; Boulares, AH; Cao, Z; Gao, B; Gariani, K; Godlewski, G; Haskó, G; Holovac, E; Horváth, B; Liaudet, L; Mukhopadhyay, P; Nemeth, BT; Pacher, P; Paloczi, J; Park, O; Persidsky, Y; Rajesh, M; Ryu, D; Varga, ZV; Wang, W; Xu, MJ; Zhou, Z | 1 |
| Chen, C; Wang, WX; Yu, J | 1 |
| Cai, W; Feng, J; Gao, G; Gong, B; Li, L; Li, Q; Ou, Z; Qi, W; Yang, X; Yang, Z; Zhao, A; Zhao, Z; Zhong, J; Zhou, T | 1 |
| Adiels, M; Barrett, PH; Bjornson, E; Boren, J; Hakkarainen, A; Hallström, BM; Kilicarslan, M; Klevstig, M; Lundbom, J; Lundbom, N; Mardinoglu, A; Marschall, HU; Nielsen, J; Serlie, MJ; Smith, U; Söderlund, S; Ståhlman, M; Taskinen, MR; Uhlén, M; Vergès, B; Watts, GF; Zhang, C | 1 |
| Miller, MA | 1 |
| Grigor'eva, IN | 1 |
7 review(s) available for nad and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The Clock-NAD
Topics: Circadian Rhythm; CLOCK Proteins; Humans; Liver; NAD; Non-alcoholic Fatty Liver Disease; Sirtuins | 2022 |
Mechanism of CD38 via NAD
Topics: ADP-ribosyl Cyclase 1; Animals; Humans; Insulin Resistance; Lipids; Liver; Membrane Glycoproteins; Mice; NAD; Non-alcoholic Fatty Liver Disease | 2023 |
Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH).
Topics: ADP-ribosyl Cyclase 1; Animals; Calcium Signaling; Humans; NAD; Non-alcoholic Fatty Liver Disease; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Signal Transduction | 2019 |
Modulation of aryl hydrocarbon receptor (AHR) and the NAD
Topics: Adipocytes; ADP-ribosyl Cyclase 1; Animals; Humans; Liver; Membrane Glycoproteins; NAD; Non-alcoholic Fatty Liver Disease; Receptors, Aryl Hydrocarbon | 2020 |
NAD
Topics: Animals; Dietary Supplements; Humans; Mice; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease | 2022 |
[Research advances in the association between deacetylase Sirtuin3 and liver diseases].
Topics: Energy Metabolism; Humans; Liver Neoplasms; Mitochondria; Mitochondrial Proteins; NAD; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Reperfusion Injury; Sirtuin 3 | 2016 |
[UDCA in the treatment of nonalcoholic fatty liver disease].
Topics: Adiponectin; Apoptosis; Cholagogues and Choleretics; Fatty Liver; Hepatocytes; Humans; Insulin; Liver X Receptors; NAD; Non-alcoholic Fatty Liver Disease; Orphan Nuclear Receptors; Receptors, G-Protein-Coupled; Ursodeoxycholic Acid | 2011 |
22 other study(ies) available for nad and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Hepatocyte-specific perturbation of NAD
Topics: Animals; Cytokines; Hepatocytes; Mice; Mice, Knockout; Mitochondria, Liver; NAD; Nicotinamide Phosphoribosyltransferase; Non-alcoholic Fatty Liver Disease; Oxidative Phosphorylation; Phenotype | 2021 |
CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD
Topics: ADP-ribosyl Cyclase 1; Animals; Diet, High-Fat; Gene Expression Regulation; Hepatocytes; Lipid Metabolism; Male; Membrane Glycoproteins; Mice; Mice, Knockout; NAD; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Signal Transduction; Sirtuins | 2021 |
The mitochondrial NAD kinase functions as a major metabolic regulator upon increased energy demand.
Topics: Animals; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mitochondria; Mitochondrial Proteins; NAD; NADP; Non-alcoholic Fatty Liver Disease; Phosphotransferases (Alcohol Group Acceptor) | 2022 |
Loss of hepatic Nmnat1 has no impact on diet-induced fatty liver disease.
Topics: Animals; Diet; Liver; Mice; Mice, Inbred C57BL; NAD; Nicotinamide-Nucleotide Adenylyltransferase; Non-alcoholic Fatty Liver Disease; Obesity | 2022 |
Metabolomic analysis shows dysregulation in amino acid and NAD+ metabolism in palmitate treated hepatocytes and plasma of non-alcoholic fatty liver disease spectrum.
Topics: Amino Acids; Hepatocytes; Humans; Kynurenine; Liver; Liver Cirrhosis; NAD; Non-alcoholic Fatty Liver Disease; Palmitates; Palmitic Acid; Tryptophan | 2023 |
Identification of Cuproptosis-Related Genes in Nonalcoholic Fatty Liver Disease.
Topics: Animals; Apoptosis; Cell Death; Computational Biology; Copper; Mice; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease | 2023 |
Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis.
Topics: Animals; Anti-Inflammatory Agents; Citric Acid Cycle; Energy Metabolism; Gene Expression Regulation; Glutamates; Homeostasis; Lipid Droplets; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Saponins; Toll-Like Receptor 4; Triterpenes | 2020 |
Sleeve gastrectomy ameliorated high-fat diet (HFD)-induced non-alcoholic fatty liver disease and upregulated the nicotinamide adenine dinucleotide +/ Sirtuin-1 pathway in mice.
Topics: Animals; Bariatric Surgery; Diet, High-Fat; Disease Models, Animal; Gastrectomy; Gene Expression; Male; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Signal Transduction; Sirtuin 1; Up-Regulation | 2021 |
Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Topics: Acrylamides; AMP-Activated Protein Kinases; Animals; Carbazoles; Cell Line; Cytokines; Diet, High-Fat; Enzyme Inhibitors; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Humans; Liver; Male; Mice; Mice, Inbred C57BL; NAD; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Non-alcoholic Fatty Liver Disease; Oleic Acid; Piperidines; Resveratrol; Signal Transduction; Sirtuin 1; Sterol Regulatory Element Binding Protein 1; Stilbenes | 2017 |
Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Obesity; Silybin; Silymarin; Sirtuin 1 | 2017 |
De novo NAD
Topics: Animals; Caenorhabditis elegans; Carboxy-Lyases; Cell Line; Choline; Conserved Sequence; Disease Models, Animal; Evolution, Molecular; Female; Gene Knockdown Techniques; Health; Hepatocytes; Homeostasis; Humans; Kidney; Liver; Longevity; Male; Methionine; Mice; Mice, Inbred C57BL; Mitochondria; NAD; Non-alcoholic Fatty Liver Disease; Rats; Sirtuins | 2018 |
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis.
Topics: Animals; Body Weight; Collagen; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Energy Metabolism; Hepatic Stellate Cells; Humans; Liver; Mice; Mice, Inbred C57BL; Muscle, Skeletal; NAD; Niacinamide; Non-alcoholic Fatty Liver Disease; Pyridinium Compounds | 2019 |
Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non-B non-C hepatitis pathogenesis.
Topics: Acetylation; Animals; Carcinoma, Hepatocellular; Case-Control Studies; Cell Hypoxia; Fatty Liver, Alcoholic; Female; Gene Expression Regulation; Hep G2 Cells; Hepatitis; Hepatitis B; Hepatitis C; Histones; Humans; Liver Neoplasms; Mice, Inbred C57BL; NAD; Non-alcoholic Fatty Liver Disease; Pregnancy; Retrospective Studies; Sirtuin 1 | 2015 |
OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Diet, High-Fat; Fatty Acids; Gene Expression Regulation; Hepatocytes; Humans; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; NAD; Neoplasm Proteins; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Oxidative Phosphorylation; Primary Cell Culture; Protein Kinase C-epsilon; Signal Transduction; Sirtuin 3 | 2015 |
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Topics: Acetylation; Animals; Apoptosis; Cytokines; Diet, High-Fat; Gene Expression; Lipid Metabolism; Liver; Male; Metabolic Networks and Pathways; Mice, Inbred C57BL; NAD; Nicotinamide Phosphoribosyltransferase; Non-alcoholic Fatty Liver Disease; Protein Processing, Post-Translational; Sirtuin 1 | 2015 |
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
Topics: Aging; Animals; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; NAD; Non-alcoholic Fatty Liver Disease | 2016 |
A conjugated fatty acid present at high levels in bitter melon seed favorably affects lipid metabolism in hepatocytes by increasing NAD(+)/NADH ratio and activating PPARα, AMPK and SIRT1 signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Dietary Supplements; Enzyme Activation; Gene Expression Regulation, Enzymologic; Hepatocytes; Hypertriglyceridemia; Hypolipidemic Agents; Linoleic Acids, Conjugated; Linolenic Acids; Male; Mice, Inbred C57BL; Momordica charantia; NAD; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Rats; Seeds; Signal Transduction; Sirtuin 1; Tumor Cells, Cultured | 2016 |
Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity.
Topics: Acetylation; Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Lipid Metabolism; Male; NAD; Non-alcoholic Fatty Liver Disease; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction; Sirtuin 1; Up-Regulation | 2016 |
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fatty Liver, Alcoholic; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD; Nitrosative Stress; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Phenanthrenes; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolines; Sirtuin 1 | 2017 |
IL-25 stimulates M2 macrophage polarization and thereby promotes mitochondrial respiratory capacity and lipolysis in adipose tissues against obesity.
Topics: 3T3-L1 Cells; Adenosine Triphosphate; Adipose Tissue; Adipose Tissue, White; Animals; Body Mass Index; Cell Polarity; Cell Respiration; Eating; Humans; Interleukin-17; Lipolysis; Liver; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mitochondria; Models, Biological; NAD; Non-alcoholic Fatty Liver Disease; Obesity; Oxygen Consumption; RNA, Messenger; Weight Gain | 2018 |
Personal model-assisted identification of NAD
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Genome; Glutathione; Glycine; Humans; Lipoproteins; Liver; Male; Metabolomics; Mice; Middle Aged; NAD; Non-alcoholic Fatty Liver Disease; Patient-Specific Modeling; Serine | 2017 |
Richer data with personalized GEMs.
Topics: Genome; Glutathione; Humans; Models, Biological; NAD; Non-alcoholic Fatty Liver Disease | 2017 |